Clinical Trial

PARP Inhibitor With 177Lu-DOTA-Octreotate PRRT in Patients With Neuroendocrine Tumours

Study acronym: PARLuNET
Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This phase 1 dose-escalation study is designed to evaluate the safety and tolerability of talazoparib in combination with 177Lu-DOTA-Octreotate peptide receptor radionuclide therapy (PRRT) in patients with metastatic pancreatic or midgut neuroendocrine tumour (NET).
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2021-09-20; most recent amendment 2025-02-18.
Trial Details
NCT Number NCT05053854
Lead Sponsor Peter MacCallum Cancer Centre, Australia
Conditions Neuroendocrine Tumors
Enrollment 24 participants
Start Date 2021-12-08
Primary Completion 2029-06-30 (estimated)
Study Completion 2029-06-30 (estimated)
Updated on ClinicalTrials.gov 2025-02-20